Poly(ε-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity

International Journal of Pharmaceutics

Volumn 158, Issue 1, 1997, Pages 19-27

  Espuelas, M S ^a   Legrand, P ^b   Irache, J M ^c   Gamazo, C ^d   Orecchioni, A M ^c   Devissaguet, J Ph ^b   Ygartua, P ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIV PARIS SUD   (France)

^c Lab de Pharmachimie et Biopharm   (France)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Absorption spectra; Amphotericin B (AmB); Circular dichroism spectra; Infrared spectra; Poly( caprolacton) nanospheres; Zeta potential

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; NANOPARTICLE; POLYCAPROLACTONE; POLYMER;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CHEMICAL INTERACTION; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; INFRARED SPECTROSCOPY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ZETA POTENTIAL;

EID: 0030732339     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00194-4     Document Type: Article

References (29)

1. Brittain, H.G., 1994. Circular dichroism studies of the self-association of amphotericin B. Chirality 6, 665-669.
2. Bolard, J., Legrand, P., Heitz, F., Cybulska, B., 1991. One-side action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 30, 5707-5715.
3. Couvreur, P., Vauthier, C., 1994. Nanoparticles: therapeutics applications and prospects. In: Albert Gdeboer (Ed.), Drug Absorption Enhancement: Concepts, Limitations and Trends. Harwood, Leiden, pp. 457-486.
4. Dubernet, C., 1995. Thermoanalysis of microspheres. Thermochim. Acta 248, 259-269.
5. Dubernet, C., Benoit, J.P., Couarraze, G., Duchene, D., 1987. Microencapsulation of nitrofurantoine in PCL: tableting and in vitro release studies. Int. J. Pharm. 35, 145-156.
6. Ernst, C., Grange, J., Rinnert, H., Dupont, G., Lematre, J., 1981. Structure of amphotericin B aggregates as revealed by UV and CD spectroscopies. Biopolymers 20, 1575-1588.
7. Fessi, H., Puisieux F., Devissaguet, J.-P., Thies, C., 1987. US Patent No. 5,118,528.
8. Ford, J.L., Timmins, P., 1989. The Use of Thermal Analysis in Polymeric Drug Delivery Systems: Techniques and Applications. Pharmaceutical Thermal Analysis. Ellis Horwood, Chichester, pp. 180-199.
9. Gaspar, R., Opperdoes, F.R., Préat, V., Roland, M., 1992. Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann. Trop. Med. Parasitol. 86, 41-49.
10. Gruda, I., Gauthier, E., Elberg, S., Brajtburg, J., Medoff, G., 1988. Effect of the detergent sucrose monolaurate on binding of amphotericin B to sterols and its toxicity for cells. Biochem. Biophys. Res. Commun. 154, 954-958.
11. Hemenger, R.P., Kaplan, T., Gray, L.J., 1983. Structure of amphotericin B aggregates based on calculations of optical spectra. Biopolymers 22, 911-918.
12. Hung, C.T., Lan, F.C., Perrier, D.G., Souter, A., 1988. A stability study of amphotericin B in aqueous media using factorial design. Int. J. Pharm. 44, 117-123.
13. Legrand, P., Romero, E.A., Cohen, B.E., Bolard, J., 1992. Effect of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob. Agents Chemother. 36, 2518-2522.
14. Legrand, P., Chéron, M., Leroy L., Bolard, J., 1996. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J. Drug Target. (in press).
15. Levine, S.T., Walsh, A., Martinez, P., Eichacker, G., Lopez Berestein, G., Natanson, C., 1991. Cardiopulmonary toxicity after liposomal amphotericin B infusions. Ann. Intern. Med. 1, 664-666.
16. Litchfield, J.T., Wilcoxon, F., 1949. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96, 99-113.
17. Mazerski, J., Grzybowska, J., Borowski, E., 1990. Influence of net charge on the aggregation and solubility behaviour of amphotericin B and its derivatives in aqueous media. Eur. Biophys. J. 18, 1-6.
18. Mbela, T.K.M., Poupaert, J.H., Dumont, P., 1992. Poly(diethylmethylidenemalonate) nano-particles as primaquine delivery system to liver. Int. J. Pharm. 79, 29-38.
19. Pahls, S., Schaffner, A., 1994. comparation of the activity of free and liposomal amphotericin B in vitro and in a model of localized murine candidiasis. J. Infect. Dis. 169, 1057-1061.
20. Ringden, O., Meunier, J., Tollemar, J., Ricci, P., Tura, S., Kuse, E., Viviani, M.A., Gorin, N.C., Klatersky, J., Fenaux, P., Prentice, H.G., Ksionski, G., 1991. Efficacy of ampho-tericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28 (Suppl. B), 73-82.
21. Rinnert, H., Thirion, C., Dupont, G., Lematre, J., 1977. Structural studies on aqueous and hydroalcoholic solutions of a polyene antibiotic: amphotericin B. Biopolymers 16, 2419-2427.
22. Rodriguez, J.M., Fessi, H., Bories, C., Puisieux, F., Devissaguet, J.-P., 1995. Primaquine-loaded poly(lactide) nanoparticles: physico-chemical study and acute tolerance in mice. Int. J. Pharm. 126, 253-260.
23. Sanchez, A., Vila-Jato, J.L., Alonso, M.J., 1993. Development of biodegragable microspheres and nanospheres for the controlled release of cyclosporin A. Int. J. Pharm. 99, 263-273.
24. Sanders, S.W., Buchi, K.N., Goddard, M.S., Lang, J.K., Tolman, K.G., 1991. Single dose pharmacokinetics and tolerance of a cholesterol sulfate complex of amphotericin B administrated to healthy volunteers. Antimicrob. Agents Chemother. 35, 1029-1034.
25. Szoka, F.C., Tang, M., 1993, Amphotericin B formulated in liposomes and lipid-based systems: a review. J. Liposome Res. 3, 363-375.
26. Tabosa do Egito, E.S., Appel, M., Fessi, H., Barrat, G., Puisieux, F., Devissaguet, J.-Ph., 1996. In-vitro and in-vivo evaluation of a new Amphotericin B emulsion-based delivery system. J. Antimicrob. Chemother. 38, 485-497.
27. Van Etten, E.W.M., Van den Heuvel-de Groot, C., Bakker-Woudenberg, I.A.J.M., 1993. Efficacies of amphotericin B-deoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J. Antimicrob. Chemother. 32, 723-739.
28. Vernier-Julienne, M.C., Vouldoukis, I., Monjour, L., Benoît, J.P., 1995. In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. J. Drug Target. 3, 23-29.
29. Vernier-Julienne, M.C., Benoit, J.P., 1996. Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm. Acta Helv. 71, 121-128.